PREXATE 12.5 mg/ 0.31 ml,solution injectable en seringue préremplie syringe, 0.31 ml
Active ingredients: Methotrexate
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 0.31 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- PREXATE 12,5 mg/ 0,31 ml,solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue(s) préremplie(s) en verre de 0,31 ml avec 1 tampon alcoolisé
- Marketing authorisation holder
- ALFASIGMA FRANCE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 21 Dec 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62744949CIP73012023CIP133400930120231Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MÉTHOTREXATEsolution | 12,5 mg · 1 seringue préremplie de 0,31 ml | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.